WaferGen Completes $15M Private Placement | GenomeWeb

NEW YORK (GenomeWeb News) — WaferGen Biosystems said today that it has completed a private placement of common stock, Series 1 convertible preferred stock, and warrants to purchase shares of common stock to accredited investors, netting just over $15 million.

WaferGen said that it intends to use the net proceeds for general corporate and working capital purposes, including sales of its SmartChip TE for next-generation sequencing target enrichment and SmartChip MyDesign for high-throughput quantitative PCR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.